What's in CAGE Bio Inc.'s pipeline?

CAGE Bio Inc. has 7 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 5 in Phase 2, 2 in Phase 1.

Which companies overlap with CAGE Bio Inc.'s portfolio?

Top competitors by shared drug class: AbbVie, AbbVie Inc., Aclaris Therapeutics, Inc., Arcutis Biotherapeutics, Inc., Azienda Ospedaliero, Universitaria Pisana.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/cage-bio-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

CAGE Bio Inc. — Portfolio Competitive Intelligence Brief

CAGE Bio Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 5 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AbbVie · 1 shared drug class
AbbVie Inc. · 1 shared drug class
Aclaris Therapeutics, Inc. · 1 shared drug class
Arcutis Biotherapeutics, Inc. · 1 shared drug class
Azienda Ospedaliero, Universitaria Pisana · 1 shared drug class
Beijing Friendship Hospital · 1 shared drug class
CTI BioPharma · 1 shared drug class
Celgene · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CAGE Bio Inc.:

Cite this brief

Drug Landscape (2026). CAGE Bio Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cage-bio-inc. Accessed 2026-05-16.